Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
IBI-363 by Innovent Biologics for Solid Tumor: Likelihood of Approval
IBI-363 is under clinical development by Innovent Biologics and currently in Phase II for Solid Tumor. According to GlobalData, Phase...
Bevacizumab biosimilar by Innovent Biologics for Recurrent Respiratory Papillomatosis (Juvenile Laryngeal Papilloma or Laryngeal Papilloma): Likelihood of Approval
Bevacizumab biosimilar is under clinical development by Innovent Biologics and currently in Phase II for Recurrent Respiratory Papillomatosis (Juvenile Laryngeal...
IBI-129 by Innovent Biologics for Solid Tumor: Likelihood of Approval
IBI-129 is under clinical development by Innovent Biologics and currently in Phase II for Solid Tumor. According to GlobalData, Phase...
Sintilimab by Innovent Biologics for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval
Sintilimab is under clinical development by Innovent Biologics and currently in Phase III for Squamous Non-Small Cell Lung Cancer. According...
Sintilimab by Innovent Biologics for Recurrent Glioblastoma Multiforme (GBM): Likelihood of Approval
Sintilimab is under clinical development by Innovent Biologics and currently in Phase II for Recurrent Glioblastoma Multiforme (GBM). According to...
IBI-343 by Innovent Biologics for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval
IBI-343 is under clinical development by Innovent Biologics and currently in Phase I for Adenocarcinoma Of The Gastroesophageal Junction. According...
IBI-343 by Innovent Biologics for Gastric Cancer: Likelihood of Approval
IBI-343 is under clinical development by Innovent Biologics and currently in Phase I for Gastric Cancer. According to GlobalData, Phase...
Sintilimab by Innovent Biologics for Pleomorphic Liposarcoma: Likelihood of Approval
Sintilimab is under clinical development by Innovent Biologics and currently in Phase II for Pleomorphic Liposarcoma. According to GlobalData, Phase...
Sintilimab by Innovent Biologics for Colorectal Cancer: Likelihood of Approval
Sintilimab is under clinical development by Innovent Biologics and currently in Phase III for Colorectal Cancer. According to GlobalData, Phase...
IBI-343 by Innovent Biologics for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval
IBI-343 is under clinical development by Innovent Biologics and currently in Phase I for Bile Duct Cancer (Cholangiocarcinoma). According to...
IBI-343 by Innovent Biologics for Solid Tumor: Likelihood of Approval
IBI-343 is under clinical development by Innovent Biologics and currently in Phase I for Solid Tumor. According to GlobalData, Phase...
IBI-343 by Innovent Biologics for Solid Tumor: Likelihood of Approval
IBI-343 is under clinical development by Innovent Biologics and currently in Phase I for Solid Tumor. According to GlobalData, Phase...
IBI-110 by Innovent Biologics for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval
IBI-110 is under clinical development by Innovent Biologics and currently in Phase II for Adenocarcinoma Of The Gastroesophageal Junction. According...
IBI-110 by Innovent Biologics for Gastric Cancer: Likelihood of Approval
IBI-110 is under clinical development by Innovent Biologics and currently in Phase II for Gastric Cancer. According to GlobalData, Phase...
Ipilimumab biosimilar by Innovent Biologics for Metastatic Biliary Tract Cancer: Likelihood of Approval
Ipilimumab biosimilar is under clinical development by Innovent Biologics and currently in Phase II for Metastatic Biliary Tract Cancer. According...
IBI-110 by Innovent Biologics for Hepatocellular Carcinoma: Likelihood of Approval
IBI-110 is under clinical development by Innovent Biologics and currently in Phase II for Hepatocellular Carcinoma. According to GlobalData, Phase...
IBI-110 by Innovent Biologics for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval
IBI-110 is under clinical development by Innovent Biologics and currently in Phase II for Squamous Non-Small Cell Lung Cancer. According...
IBI-3002 by Innovent Biologics for Asthma: Likelihood of Approval
IBI-3002 is under clinical development by Innovent Biologics and currently in Phase I for Asthma. According to GlobalData, Phase I...
IBI-343 by Innovent Biologics for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
IBI-343 is under clinical development by Innovent Biologics and currently in Phase I for Pancreatic Ductal Adenocarcinoma. According to GlobalData,...
IBI-130 by Innovent Biologics for Solid Tumor: Likelihood of Approval
IBI-130 is under clinical development by Innovent Biologics and currently in Phase II for Solid Tumor. According to GlobalData, Phase...